BDD 2020 Online - Posters

24 avril 2020
Jetez un coup d'œil à nos affiches BDD 2020 et écoutez les points fondamentaux enregistrés par les auteurs.
P1

Poster 1

Efficacy and Safety of Baricitinib in Moderate to Severe Atopic Dermatitis: Results of Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2.

P2

Poster 2

Rapid and Concurrent Improvements in Signs and Symptoms of Atopic Dermatitis with Baricitinib in Phase 3 Studies.

P3

Poster 3

A Belgian Consensus On The Definition Of A Treat-To-Target Outcome Set In Psoriasis Management.

P4

Poster 4

Novel mutation in the ichthyin gene erroneously diagnosed and treated as ‘Ichthyosis vulgaris’ and ‘Psoriasis’.

View the poster more closely

P5

Poster 5

The many faces of granulomatous facial eruptions: a case report of granulomatous acne rosacea.

P6

Poster 6

Secondary resistance to Vismodegib through acquired pathogenic SMO mutations: a case series.

P7

Poster 7

Skin parameter maps in multispectral dermoscopy.

P8

Poster 8

Utility of patch testing for the diagnosis of delayed-type hypersensitivity reactions to clindamycin.

P9

Poster 9

Diagnostic approach to harlequin syndrome: a case report.

202004 19c20 poster Myth SKIN

Poster 10

Myth, belief and dogmatic thinking moves into hair science and technology during our XXIst century.

P11

Poster 11

Secukinumab sustainability: The Belgian Experience.

P12

Poster 12

Acral pigmented lesions: do dermoscopy!

View the poster more closely

P13

Poster 13

Inspect the skin, but don’t forget the brain: a case of Giant Congenital Melanocytic Nevus in a newborn.

P14

Poster 14

Optimizing skin cancer detection in the general population: an early access lesion-directed consultation.

P15

Poster 15

Nailfold videocapillaroscopy: a diagnostic tool when clinical evaluation is misleading.

P16

Poster 16

Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis.

P17

Poster 17

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 12-Week Efficacy, Safety, and Speed of Response from a Randomized, Double-Blinded Trial.

P18 202004 19d11 poster Acad SKIN

Poster 18

A unique collection of books focussing on hair and skin at the "Fonds Van Neste".

Lire la suite?

Devenez membre de la Société Royale Belge de Dermatologie et Vénérologie (SRBDV) et l'Union Professionnelle Belge de Dermatologie et Vénérologie (UPBDV)) !

Votre cotisation vous donne droit à une série d’avantages, comme un accès illimité à la partie 'members only' de ce site web, mais aussi une inscription fortement réduite aux Belgian Dermatology Days (BDD) qui est organisé annuellement.
En plus l’accès au site web de l'Union Professionnelle et des newsletters envoyées par mail pour les nouvelles informations importantes. Il y a aussi une importante réduction de votre cotisation pour les listes des allergènes sur le site des allergies de contact. et une assurance professionnelle en responsabilité civile qui a été développée spécifiquement pour notre discipline.